Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden
Menée en Suède et au Danemark à partir de données portant sur 11 874 patientes atteintes d'un cancer de l'ovaire (âge : 30-84 ans) et sur 473 960 témoins, cette étude analyse l'association entre une utilisation de faibles doses d'aspirine et le risque de développer la maladie
Background: Studies on association between low-dose aspirin use and ovarian cancer risk were mostly based on self-reported medication use and few had large enough sample size to investigate the potential modification effect by ovarian cancer risk factors. Methods: In these two nationwide nested case-control studies among the Danish and Swedish female population, 11,874 women with ovarian cancer (30–84 years old) (Denmark: 7328 diagnosed in 2000–2019, Sweden: 4546 diagnosed in 2010–2018) were randomly age- matched with 473,960 female controls (293,120 from Denmark, and 181,840 from Sweden). We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI) and combined the estimates based the fixed-effect assumption. Effect modification by inflammation-related risk factors and by indication (cardiovascular disease, CVD) were also investigated. Results: Ever use of low-dose aspirin was not strongly associated with the overall risk of ovarian cancer (OR = 0.97; 95%CI: 0.92–1.03). However, the association differed according to parity (nulliparous: OR = 0.80, 95%CI: 0.70–0.92; parous: OR = 1.00, 95%CI: 0.94–1.07; p-interaction = 0.0024), and according to history of CVD (no CVD: OR = 0.91, 95%CI: 0.82–1.00; ever CVD: OR = 1.05, 95%CI: 0.97–1.13; p-interaction =0.0204). Conclusions: Low-dose aspirin use was associated with a decreased ovarian cancer risk especially in nulliparous women and in women without CVD diagnosis.